- Dr. Bischofberger was at Gilead Sciences for almost 30 years
- Kronos completed $18 million seed financing
- The company is advancing two programs built on its small molecule microarray (SMM) platform
Kronos Bio, Inc. (Kronos) announced on 5/23/18 the appointment of Norbert Bischofberger, Ph.D. as its President and Chief Executive Officer and completion of an $18 million seed financing. Prior to joining Kronos, Dr. Bischofberger was at Gilead Sciences for almost 30 years, where he most recently served as Executive Vice President, Research and Development and Chief Scientific Officer until April 2018.
The financing was led by a number of industry leaders and venture capital funds, including Omega Funds, BellCo Capital, John Martin, Ph.D., Norbert Bischofberger, Ph.D., and Vida Ventures, LLC. As part of this financing, Drs. Bischofberger and Martin, as well as Rebecka Belldegrun, M.D., and Otello Stampacchia, Ph.D. joined the company’s Board of Directors.
Kronos is pursuing therapies for some of the most intractable cancer targets. The company employs high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology.
Kronos is currently advancing two preclinical programs built upon hits identified from the SMM platform, targeting MYC and the Androgen Receptor (AR). The MYC family of transcription factors are master regulators of cell proliferation and differentiation, and MYC expression is dysregulated in a large proportion of human cancers. Kronos is currently pursuing lead compounds that have demonstrated activity in multiple MYC-driven cancer models. The Androgen Receptor (AR) is a primary driver of disease progression in prostate cancer. Kronos is progressing multiple hit series that target AR and its splice variants and have been shown to reduce viability and AR expression in treatment-resistant cell lines.
“While we can lay the framework in an academic setting, the speed with which progress can be made with the right team of commercial scientists is greatly accelerated. This next stage of development will uncover the real therapeutic potential of this research for patients,” said Dr. Angela Koehler, Assistant Professor, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology (MIT) and a Scientific Founder of Kronos. “I am thrilled to have the opportunity to work closely with Norbert and together advance our research to benefit patients with intractable cancers.”